Healthcare is a great place to invest right now. Whether you believe that 2021 will be the last year that we’re worrying much about COVID-19, or you believe that Moderna CEO Stephane Bancel is right and that this coronavirus will be around forever (though not as a pandemic-level threat), there’s little doubt that there will be strong demand for quality healthcare services.
I see two healthcare stocks as having the potential to soar this year for very different reasons. American Well (NYSE:AMWL), or Amwell, could benefit from continued high demand for telehealth services, while AmerisourceBergen (NYSE:ABC) is positioned to thrive if conditions in the sector start getting back to normal and there’s an uptick in pharmaceutical sales.
1. The case for Amwell
Telehealth company Amwell only began trading publicly on Sept. 17. The stock is up around 30% since then (while the S&P 500 is up 15%), and there could be more gains to come. At a market cap of $7 billion, Amwell is just a fraction of the size of rival Teladoc Health, which is now worth more than $40 billion after its merger with Livongo Health. And the numbers Amwell has been generating have been phenomenal.
When it released its third-quarter results on Nov. 12, Amwell reported 1.4 million telehealth visits for the period — a 450% increase year over year. Revenues of $62.6 million were up by 80%. Although the company did incur a net loss of $64.6 million, poor bottom-line performances haven’t exactly hurt Teladoc — it has posted losses in each of its past five quarters.
And Amwell could accelerate its growth by making it easier for hospitals to offer telehealth services. On Feb. 18, it announced the launch of Hospital TV 100, a device that will allow hospitals to convert televisions they already have into telehealth endpoints. These can enhance social distancing and safety for health professionals while making it easier for them to keep tabs on patients.
Even though healthcare professionals are administering COVID-19 vaccines at a fairly rapid clip, it could still be some time before the pandemic is over. And in the meantime, the demand for telehealth services will remain high.
With its smaller size and a focus mainly on telehealth (Teladoc, by contrast, has been expanding into other areas, such as chronic condition management), Amwell is more of a pure-play in this area than its rival is. That could give it more of an opportunity to soar if demand for telehealth services intensifies this year.
2. The case for AmerisourceBergen
Some investors may want to hedge their bets optimistically for the possibility that the spread of COVID-19 will keep declining sharply, to the point where hospital operations will be able to start getting back to normal. One way to do that would be to invest in medical distribution company AmerisourceBergen.
For the past year, patients haven’t been eager to visit physicians or hospitals due to fear of contracting the coronavirus. That has been a headwind for sales of pharmaceutical products.
In AmerisourceBergen’s fiscal 2020 third quarter, which ended June 30, sales were up just 0.3% year over year, due in part to COVID-19; sales had been pulled forward as consumers stocked up on pharmaceuticals during the early stage of the pandemic. In its fiscal fourth quarter, sales growth bounced back to 7.9%. And when it released its fiscal 2021 first-quarter results on Feb. 4 (for the final three months of calendar 2020), revenues reached $52.5 billion and were growing at an even higher rate — 9.7%. AmerisourceBergen also upgraded its guidance for fiscal 2021. Previously, it had been forecasting growth to be in the mid-single-digit percentages. Now, it expects growth in the high-single-digit percentages.
One reason to be upbeat about its growth prospects — the company is expanding. Earlier this year, AmerisourceBergen acquired the majority of Alliance Healthcare from Walgreens Boots Alliance for $6.5 billion. The move will help expand the company’s footprint, particularly in Europe, where Alliance is among the largest pharmaceutical wholesalers. While Walgreens and AmerisourceBergen work together under a strategic partnership in the U.S. and the pharmacy retailer owns close to 30% of AmerisourceBergen, the two companies focus on different areas: wholesale vs. retail.
Over the past 12 months, shares of AmerisourceBergen are up a modest 8%, while the S&P 500 has increased by 16%. However, once patient visits rise to pre-pandemic levels, pharmaceutical products should see greater demand. That alone should drive up the stock. Additionally, AmerisourceBergen’s acquisition of Alliance is another reason to be bullish about its prospects in 2021.
This article represents the opinion of the writer(s), who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.
MyWallSt operates a full disclosure policy. MyWallSt staff currently holds long positions in companies mentioned above. Read our full disclosure policy here.
Guest Author at MyWallSt
The Motley Fool has been one of the industry's experts for years and is one of our contributors here at MyWallSt.